Kristyn Meadows
Family · Austin, TXNPI 1649058777
Payments from drug & device makers
Across 94 payments — averaging $27.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Arcutis Biotherapeutics, Inc.$519
- AbbVie$329
- Incyte Corporation$292
- UCB, Inc.$219
- Bayer$203
- AstraZeneca$173
- plus $873 from 15 others
What the payments were for
- Food & beverage$2,51096%
- Education$994%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Arcutis Biotherapeutics, Inc. | 19 | $519 |
| AbbVie | 16 | $329 |
| Incyte Corporation | 7 | $292 |
| UCB, Inc. | 8 | $219 |
| Bayer | 6 | $203 |
| AstraZeneca | 8 | $173 |
| Galderma Laboratories, L.p. | 1 | $149 |
| Novartis | 6 | $130 |
| E.r. Squibb & Sons, L.L.C. | 1 | $121 |
| Mayne Pharma Commercial LLC | 7 | $115 |
| Astellas Pharma US Inc | 1 | $99 |
| Novo Nordisk | 3 | $48 |
| Lilly USA, LLC | 2 | $35 |
| Idorsia Pharmaceuticals US Inc | 2 | $30 |
| Otsuka America Pharmaceutical, Inc. | 1 | $28 |
| Springworks Therapeutics, Inc. | 1 | $27 |
| Boehringer Ingelheim | 1 | $23 |
| Pfizer | 1 | $21 |
| Paratek Pharmaceuticals, Inc. | 1 | $17 |
| Botanix SB Inc | 1 | $15 |
| Biofrontera Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,609 in reported general payments places this provider in the 85th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 26 | $29,988 |
| FarxigaDapagliflozin Propanediol | 27 | $28,819 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $21,024 |
| TrulicityDulaglutide | 12 | $19,228 |
| JardianceEmpagliflozin | 12 | $15,311 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 64 | $2,233 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 11 | $1,860 |
| Atorvastatin Calcium | 133 | $1,191 |
| Fluticasone Propionate | 45 | $936 |
| Bupropion XlBupropion Hcl | 13 | $859 |
| Duloxetine Hcl | 21 | $738 |
| Gabapentin | 50 | $663 |
| Hydroxyzine Hcl | 23 | $622 |
| Alprazolam | 119 | $619 |
| Omeprazole | 29 | $517 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $48 | $29,98826 claims |
| AstraZenecaFarxiga | $173 | $28,81927 claims |
| Lilly USA, LLCTrulicity | $35 | $19,22812 claims |
| Boehringer IngelheimJardiance | $23 | $15,31112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 15,456 family providers in Texas.
Other family in Austin
- Nirupama JeromeAustin$418K
- Jean ChenAustin$176K
- Monique MulvanyAustin$142K
- Barry HughesAustin$51K
- Eric PerezAustin$42K
- Chelsea CrillyAustin$36K
- Alexandra RossiAustin$35K
- Angelina DetmersAustin$33K
- Lashonda CraneHouston$3.4M
- David WeirDallas$959K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.